¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"glucose effect"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antagonistic effect
    ´ëÇ×È¿°ú
  • anticoagulant effect
    Ç×ÀÀ°íÈ¿°ú
  • antioxidant effect
    Ç×»êÈ­È¿°ú
  • antitussive effect
    Ç×±âħȿ°ú, ÁøÇØÈ¿°ú
  • additive effect
    ºÎ°¡È¿°ú
  • adverse effect
    À¯ÇØÈ¿°ú
  • beam hardening effect
    ºö°æÈ­È¿°ú
  • back-pressure effect
    ÈĹæ¾Ð·ÂÈ¿°ú
  • biologic effect
    »ý¹°ÇÐÀûÈ¿°ú
  • bacteriostatic effect
    Á¤±ÕÈ¿°ú
  • blow back effect
    µÞ¹Ù¶÷È¿°ú, ÈÄdzȿ°ú
  • cohort effect
    ÄÚȣƮȿ°ú
  • combined effect
    º´¿ëÈ¿°ú
  • concentration effect
    ³óµµÈ¿°ú
  • cumulative effect
    ´©ÀûÈ¿°ú, ÃàÀûÈ¿°ú
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • stochastic effect
    È®·ü·ÐÀûÈ¿°ú
  • synergistic effect
    »ó½ÂÈ¿°ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acute normal tissue effect
    Á¤»óÁ¶Á÷±Þ¼º¿µÇâ
  • additive effect
    ºÎ°¡È¿°ú, »ó°¡È¿°ú
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • antagonistic effect
    ¸Â¹öÆÀÈ¿°ú, ´ëÇ×È¿°ú
  • anticoagulant effect
    Ç×ÀÀ°íÈ¿°ú
  • antioxidant effect
    Ç×»êÈ­È¿°ú
  • antitoxemic effect
    Ç×µ¶Ç÷ÁõÈ¿°ú
  • antitussive effect
    Ç×±âħȿ°ú, ÁøÇØÈ¿°ú
  • back-pressure effect
    ÈĹæ¾Ð·ÂÈ¿°ú
  • bacteriostatic effect
    Á¤±ÕÈ¿°ú
  • beam hardening effect
    ºö°æÈ­È¿°ú
  • binaural hearing effect
    µÎ±Íµè±âÈ¿°ú
  • biologic effect
    »ý¹°ÇÐÀûÈ¿°ú
  • blow back effect
    µÞ¹Ù¶÷È¿°ú, ÈÄdzȿ°ú
  • bridle effect
    °í»ßÈ¿°ú, Á¦¾îÈ¿°ú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glucose 6 phosphate dehydrogenase def
    ±Û·çÄÚ¿À½º-6-Àλê Å»¼ö¼Ò È¿¼Ò°á
  • glucose dehydrogenase
    ±Û·çÄÚ¿À½ºÅ»¼ö¼ÒÈ¿¼Ò, ±Û·çÄÚ¿À½ºµ¥È÷µå·Î°Ô³ªÁ¦.
  • glucose equivalent
    ±Û·çÄÚ¿À½º´ç·®.
  • glucose fermenter
    Æ÷µµ´ç¹ßÈ¿¼Ò
  • glucose fluctuation
    Æ÷µµ´çº¯µ¿
  • glucose insulin tolerance test =GITT
    Æ÷µµ´çÀν¶¸°ºÎÇϽÃÇè.
  • glucose intolerance
    Æ÷µµ´ç ºÒ³»¼º
  • glucose lactate cycle
    ±Û·çÄÚ¿À½º¶ôÆ®»ê ȸ·Î.
  • glucose level
    Æ÷µµ´çÄ¡<--ÁØÀ§>
  • glucose measurement
    Æ÷µµ´çÃøÁ¤
  • glucose monitoring
    Æ÷µµ´ç°¨½Ã
  • glucose oxidase
    Æ÷µµ´ç»êÈ­È¿¼Ò
  • glucose oxidase =GOD
    ±Û·çÄÚ¿À½º »êÈ­È¿¼Ò(¡­ß«ûùý£áÈ), ±Û·çÄÚ¿À½º¿Á½Ã ´ÙÁ¦.
  • glucose oxidizer
    Æ÷µµ´ç»êÈ­Á¦
  • glucose oxydase test
    Æ÷µµ´ç»êÈ­È¿¼Ò¹ý.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glucose 6 phosphate dehydrogenase =G 6 PD
    ±Û·çÄÚ¿À½º 6Àλê Å»¼ö ¼ÒÈ¿¼Ò, ±Û·çÄÚ¿À½º-6-ÀÎ»ê µ¥È÷µå·Î°Ô³ªÁ¦.
  • glucose 6 phosphate dehydrogenase def
    ±Û·çÄÚ¿À½º-6-Àλê Å»¼ö¼Ò È¿¼Ò°á
  • glucose dehydrogenase
    ±Û·çÄÚ¿À½ºÅ»¼ö¼ÒÈ¿¼Ò, ±Û·çÄÚ¿À½ºµ¥È÷µå·Î°Ô³ªÁ¦.
  • glucose equivalent
    ±Û·çÄÚ¿À½º´ç·®.
  • glucose fermenter
    Æ÷µµ´ç¹ßÈ¿¼Ò
  • glucose fluctuation
    Æ÷µµ´çº¯µ¿
  • glucose insulin tolerance test =GITT
    Æ÷µµ´çÀν¶¸°ºÎÇϽÃÇè.
  • glucose intolerance
    Æ÷µµ´ç ºÒ³»¼º
  • glucose lactate cycle
    ±Û·çÄÚ¿À½º¶ôÆ®»ê ȸ·Î.
  • glucose level
    Æ÷µµ´çÄ¡<--ÁØÀ§>
  • glucose measurement
    Æ÷µµ´çÃøÁ¤
  • glucose monitoring
    Æ÷µµ´ç°¨½Ã
  • glucose oxidase
    Æ÷µµ´ç»êÈ­È¿¼Ò
  • glucose oxidase =GOD
    ±Û·çÄÚ¿À½º »êÈ­È¿¼Ò(¡­ß«ûùý£áÈ), ±Û·çÄÚ¿À½º¿Á½Ã ´ÙÁ¦.
  • glucose oxidizer
    Æ÷µµ´ç»êÈ­Á¦
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anomeric effect
    ¾Æ³ë¸Ó¿µÇâ(ç¯úÂ)
  • asymmetry effect
    ºÎÀçÈ¿°ú(Üôî²üùÍý)
  • Blinks effect
    ºí¸°Å©½º È¿°ú(üùÍý) (ÔÒ) chromatic transient
  • Bohr effect
    º¸¾î È¿°ú(üùÍý)
  • charge effect
    ÀüÇÏÈ¿°ú(ï³ùÃüùÍý)
  • chronotropic effect
    º¯½Ã¼ºÈ¿°ú(ܨãÁàõüùÍý)
  • cis effect
    ½Ã½º È¿°ú(üùÍý)
  • Compton effect
    ÄÞÅæ È¿°ú(üùÍý)
  • Cotton effect
    ÄÚÅæ È¿°ú(üùÍý)
  • Coulomb effect
    "Äí·Õ È¿°ú(üùÍý),(ÔÒ) ion-ion interaction"
  • Crabtree effect
    Å©·¡ºêÆ®¸® È¿°ú(üùÍý)
  • dispersion effect
    "ºÐ»ê È¿°ú(ÝÂߤüùÍý), (ÔÒ) dispersion forces"
  • Dorn effect
    "µ· È¿°ú(üùÍý), (ÔÒ) sedimentation potential"
  • drag effect
    ²ø¸² È¿°ú(üùÍý) (ÔÒ) solvent drag
  • dual-effect mutant
    ÀÌÁßÈ¿°ú º¯ÀÌü(ì£ñìüùÍýܨì¶ô÷)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gradient induced phase shift effect
    °æ»çÀ¯µµ À§»óº¯À§È¿°ú
  • halo effect
    ´Þ¹«¸®È¿°ú
  • immediate effect
    Áﰢȿ°ú, Áï½ÃÈ¿°ú
  • in-flow effect
    À¯ÀÔ È¿°ú
  • iron effect
    öȿ°ú
  • mach effect
    ¸¶ÇÏÇö»ó
  • magnetization transfer effect
    ÀÚÈ­Àü´ÞÈ¿°ú
  • main effect
    ÁÖÀÛ¿ë
  • mass effect
    Á¾±«È¿°ú
  • misregistration effect
    ¿Àµî·ÏÈ¿°ú
  • oblique angle effect
    »ç°¢È¿°ú
  • paramagnetic susceptibility effect
    »óÀÚ¼ºÀÚ±âÈ­È¿°ú
  • partial volume effect
    ºÎºÐ¿ëÀûÈ¿°ú
  • phase shift effect
    À§»óº¯À§È¿°ú
  • photoelectric effect
    ±¤ÀüÈ¿°ú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LAE   1) Late Asthmatic Effect
  2) Left Atrial Enlargement
SE Side Effect
AE above-elbow [amputation]; acrodermatitis enteropathica; activation energy; adult erythrocyte; advers...
AEF allogenic effect factor; amyloid enhancing factor; aorto-enteric fistula
CE California encephalitis; cardiac enlargement; cardioesophageal; carotid endarterectomy; catamenial e...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DEF Dose Effect Factor
ES Effect Size
HWE Healthy Worker Effect
ISFET Ion Sensitive Field Effect Transistor
LOAEL Lowest Observed Adverse Effect Level
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • carriar effect
    ´ãü È¿°ú
    Ha
  • carry effect
    ¿î¹Ý È¿°ú
  • cavitation effect
    °øµ¿ È¿°ú
  • clasp knife effect
    Á¢´Â Ä® È¿°ú
  • cytopathogenic effect
    ¼¼Æ÷ º¯¼º Çö»ó, ¼¼Æ÷ º´º¯ È¿°ú
  • Deelman`s effect
    µ¨¸¸ È¿°ú
  • detergent effect
    Á¤È­ ÀÛ¿ë
  • domino effect
    µµ¹Ì³ë È¿°ú
  • Donnan effect
    µµ³­ È¿°ú
  • Doppler effect
    µµÇ÷¯ È¿°ú, Doppler È¿°ú
    1. ±Ù¿øÁö¿¡ ´ëÇÑ ¼ö½ÅÁöÀÇ »ó´ëÀûÀÎ ¿îµ¿À¸·ÎºÎÅÍ ¾ß±âµÇ´Â Á֯ļöÀÇ ¸í¹éÇÑ º¯È­. 2. ¾î¶² ¹°Ã¼°¡ ¿îµ¿ »óÅ¿¡ ÀÖÀ» ¶§ ³ªÅ¸³ª´Â ¹ÝÇâµÇ´Â ¹æ»ç¼±¿¡¼­ Áøµ¿¼öÀÇ º¯È­´Â µµÇ÷¯ È¿°úÀÇ °á°úÀÌ´Ù. ¹æ»ç¼±ÀÇ ±Ù¿øÀ¸·ÎºÎÅÍ ¶³¾îÁø ¹°Ã¼ÀÇ ¿îµ¿Àº Á¤Áö »óÅÂÀÇ ¹°Ã¼¿¡ ºñ±³ÇØ º¼ ¶§ ´õ ³·Àº Áøµ¿¼öÀÇ ¹ÝÇâÀ» ÀÏÀ¸Å³ °ÍÀÌ´Ù. ¹æ»ç¼±ÀÇ ±Ù¿øÀ» ÇâÇÑ ¿îµ¿Àº ´õ ³ôÀº Áøµ¿¼ö¸¦ ÀÏÀ¸Å²´Ù.
  • dose rate effect
    ¼±·®À² È¿°ú
  • dose-effect relationship
    ¼±·® ¿µÇâ °ü°è
  • double effect
    ÀÌÁß È¿°ú
  • drug side effect
    ºÎÀÛ¿ë
  • efferent effect
    ¿ø½É È¿°ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
glucose-1-phosphate kinase <enzyme> An enzyme that, in the presence of ATP, catalyses the phosphorylation of d-glucose 1-phosphate to form d-glucose 1,6-bisphosphate and ADP; found in yeast and muscle; d-glucose 1,6-bisphosphate is a required cofactor of one of the enzymes in glycogenolysis.
Synonym: glucose-1-phosphate kinase.
(05 Mar 2000)
glucose-1-phosphate phosphodismutase A phosphotransferase catalyzing the reversible transfer of a phosphate residue from one d-glucose 1-phosphate to another, yielding d-glucose 1,6-bisphosphate and d-glucose. This enzyme provides a crucial intermediate needed for glucose-phosphate isomerase.
(05 Mar 2000)
glucose-1-phosphate uridylyltransferase <enzyme> An enzyme that activates d-glucose by reacting d-glucose 1-phosphate with UTP, producing pyrophosphate and UDP glucose; a crucial step in glycogen biosynthesis.
(05 Mar 2000)
glucose-1-phospho-D-mannosylglycoprotein phosphodiesterase <enzyme> Removes the glucose-1-phosphate from glc-alpha-1-p-6-mannose residues in glycoproteins as a unit; pH optimum 7.5
Registry number: EC 3.1.4.51
Synonym: ag1p phosphodiesterase, alpha-glucose-1-phosphate phosphodiesterase
(26 Jun 1999)
glucose-3-phosphatase <enzyme> From rat liver; has glucose-3-phosphate hydrolytic activity
Registry number: EC 3.1.3.-
(26 Jun 1999)
glucose-6-dehydrogenase deficiency <biochemistry> An inherited condition that results in a deficiency in glucose-6-phosphate dehydrogenase. Particular drugs (sulphonamides) can exacerbate this problem. The result is haemolytic anaemia.
(27 Sep 1997)
glucose-6-phosphatase <enzyme> An enzyme that catalyses the conversion of d-glucose-6-phosphate and water to d-glucose and orthophosphate. This enzyme is deficient in glycogen storage disease Ia.
Chemical name: D-Glucose-6-phosphate phosphohydrolase
Registry number: EC 3.1.3.9
(12 Dec 1998)
glucose-6-phosphatase hepatorenal glycogenosis Glycogenosis due to glucose-6-phosphatase deficiency, resulting in accumulation of excessive amounts of glycogen of normal chemical structure, particularly in liver and kidney.
Synonym: Gierke's disease, glucose-6-phosphatase hepatorenal glycogenosis, von Gierke's disease.
(05 Mar 2000)
glucose-6-phosphate <biochemistry> Glucose 6-phosphate is a phosphomonoester of glucose that is formed by transfer of phosphate from ATP, catalysed by the enzyme hexokinase.
It is an intermediate both of the glycolytic pathway (next converted to fructose 6 phosphate) and of the NADPH generating pentose phosphate pathway, formed from glucose via hexokinase. However it is not strictly a glycolytic intermediate and it is readily converted to glycogen or oxidized to NADPH.
(10 Oct 1997)
glucose-6-phosphate dehydrogenase <enzyme> An NADP+ enzyme that catalyses the dehydrogenation (oxidation) of d-glucose-6-phosphate to 6-phospho-d-glucono-d-lactone, this reaction initiating the Dickens shunt.
Deficiency of this enzyme is the commonest disease-causing enzyme defect in humans affecting an estimated 400 million people.
The gene for this enzyme is on the X chromosome. Males with the enzyme deficiency develop haemolytic anaemia when red blood cells are exposed to oxidant drugs such as the antimalarial primaquine, the sulfonamide antibiotics or sulfones, naphthalene moth balls, or fava beans.
Synonym: Robison ester dehydrogenase, Zwischenferment.
Acronym: G6PD
(12 Sep 2002)
glucose-6-phosphate dehydrogenase deficiency A deficiency of glucose-6-phosphate dehydrogenase, an enzyme important for maintaining cellular concentrations of reduced nucleotides.
Deficiency of this enzyme is the commonest disease-causing enzyme defect in humans affecting an estimated 400 million people.
The gene for this enzyme is on the X chromosome and there are various polymorphic forms.
Males with the enzyme deficiency develop haemolytic anaemia when red blood cells are exposed to oxidant drugs such as the antimalarial primaquine, the sulfonamide antibiotics or sulfones, naphthalene moth balls, or fava beans. It can also cause anaemia of the newborn, and chronic nonspherocytic haemolytic anaemia.
Inheritance: X-linked.
(12 Sep 2002)
glucose-6-phosphate isomerase <enzyme> An enzyme that catalyses the reversible interconversion of glucose-6-phosphate and fructose-6-phosphate, and is a part of the glycolytic and gluconeogenic pathways. Deficiency of the enzyme, an autosomal recessive trait, results in liver glycogenesis and haemolytic anaemia.
Chemical name: D-Glucose-6-phosphate ketol-isomerase
Registry number: EC 5.3.1.9
(12 Dec 1998)
glucose-6-phosphate translocase <enzyme> A component of EC 3.1.3.9 which transports glucose phosphate into endoplasmic reticulum
Registry number: EC 2.7.-
Synonym: t1 transport protein
(26 Jun 1999)
glucose clamp technique <technique> Maintenance of a constant blood glucose level by perfusion or infusion with glucose or insulin. It is used for the study of metabolic rates (e.g., in glucose, lipid, amino acid metabolism) at constant glucose concentration.
(12 Dec 1998)
glucose dehydrogenase <enzyme> Converts beta-d-glucose to d-glucono-d-lactone, transferring hydrogen to NAD+ or NADP+.
Compare: glucose oxidase.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • halo effect
    Èı¤ÀÇ È¿°ú !
  • hothouse effect
    =greenhouse effect
  • inertia effect
    °ü¼ºÈ¿°ú !
  • key stone effect
    (È­¸éÀÇ) À§°¡ ÆÛÁö´Â Çö»ó
  • packing effect
    °áÇÕ È¿°ú !
  • photoelectric effect
    ±¤ÀüÈ¿°ú
  • ram effect
    ·¥ È¿°ú(±â¼Ó)ÀÇ Áõ°¡¿¡ µû¶ó ÈíÀÔ±¸¿¡ À¯ÀԵǴ °ø±âÀÇ ¾Ð·ÂÀÌ Áõ°¡ÇÏ´Â È¿°ú) '
  • ratchet effect
    ´Ü¼ÓÀû È¿°ú 
  • ripple effect
    ÆÄ±Þ È¿°ú !
  • shot effect,the
    (Áø°ø°üÀÇ À½±Ø¿¡¼­ ¹æ»çµÇ´Â ¿­ÀüÀÚÀÇ)»êź È¿°ú ''
  • side effect
    ºÎÀÛ¿ë
  • skin effect
    (Á֯ļö ÀüµµÃ¼ÀÇ)Ç¥ÇÇ È¿°ú
  • stage effect
    ¹«´ë È¿°ú
  • tunnel effect
    ÅͳΠȿ°ú !
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á